Distribution of Colloidal Radioactive Chromic Phosphate after Intracavitary Administration

Root, Samuel W.; Tyor, Malcolm P.; Andrews, Gould A.; Kniseley, Ralph M.

doi:10.1148/63.2.251

Cited by 35 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An early report on the use of 32 P chromic phosphate in both intrapleural and intraperitoneal administrations showed a 5% accumulation of the injected activity in urine within 11 days, which can be shown to build up to a total urinary clearance pathway of 9% with, however, a huge interpatient variation (Root et al 1954). It is therefore assumed that 90% of the activity remains within the pleural cavity; corrections for the clearance kinetics of the remaining 10% are not performed as the average kinetics derived from Root et al (1954) showed it to be comparable in size to the observed interpatient variation. For this study, we have therefore assumed that the lung dose builds up exponentially with the 14.29 day physical half-life of 32 P. The doses are reached asymptotically; 95% of the maximum dose is obtained within 62 days.…”

Section: Introductionmentioning

confidence: 99%

Pediatric dosimetry for intrapleural lung injections of³²P chromic phosphate

Konijnenberg¹,

Olch²

2010

Phys. Med. Biol.

View full text Add to dashboard Cite

Intracavitary injections of (32)P chromic phosphate are used in the therapy of pleuropulmonary blastoma and pulmonary sarcomas in children. The lung dose, however, has never been calculated despite the potential risk of lung toxicity from treatment. In this work the dosimetry has been calculated in target tissue and lung for pediatric phantoms. Pleural cavities were modeled in the Monte Carlo code MCNP within the pediatric MIRD phantoms. Both the depth-dose curves in the pleural lining and into the lung as well as 3D dose distributions were calculated for either homogeneous or inhomogeneous (32)P activity distributions. Dose-volume histograms for the lung tissue and isodose graphs were generated. The results for the 2D depth-dose curve to the pleural lining and tumor around the pleural cavity correspond well with the point kernel model-based recommendations. With a 2 mm thick pleural lining, one-third of the lung parenchyma volume gets a dose more than 30 Gy (V(30)) for 340 MBq (32)P in a 10 year old. This is close to lung tolerance. Younger children will receive a larger dose to the lung when the lung density remains equal to the adult value; the V(30) relative lung volume for a 5 year old is 35% at an activity of 256 MBq and for a 1 year old 165 MBq yields a V(30) of 43%. At higher densities of the lung tissue V(30) stays below 32%. All activities yield a therapeutic dose of at least 225 Gy in the pleural lining. With a more normal pleural lining thickness (0.5 mm instead of 2 mm) the injected activities will have to be reduced by a factor 5 to obtain tolerable lung doses in pediatric patients. Previous dosimetry recommendations for the adult apply well down to lung surface areas of 400 cm(2). Monte Carlo dosimetry quantitates the three-dimensional dose distribution, providing a better insight into the maximum tolerable activity for this therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Pediatric dosimetry for intrapleural lung injections of³²P chromic phosphate

Konijnenberg¹,

Olch²

2010

Phys. Med. Biol.

View full text Add to dashboard Cite

show abstract

“…The chromic radiophosphate has been used extensively for irradiation of tumors (3)(4)(5)(6), palliation of malignant effusions (7)(8)(9), and for prophylaxis following surgical tumour removal (10)(11)(12)(13)(14).…”

mentioning

confidence: 99%

Colloidal Chromic Phosphate: its Biological Behaviour

Anghileri¹

1967

Nuklearmedizin

View full text Add to dashboard Cite

SummaryThe distribution within the body of various types of colloidal chromic phosphate (51Cr32PO4) at different times after intravenous and intraperitoneal injection has been studied. The possible hydrolysis “in situ” of the chromic phosphate was determined by studying the ratio β-activity / γ-activity. Similar studies have been performed with the different fractions of bone. The true colloidal chromic phosphate — in contrast to the particulated one — migrates in 50% of the cases to the liver 24 h after intraperitoneal administration. This behavior indicates the usefulness of this type of preparation for postoperative tumor prophylaxis.

show abstract

“…Search was therefore made for pure betaemitting isotopes with appropriate characteristics, and interest has centred mainly on two such: (I) phosphorus-32 in the form of colloidal chromic phosphate, and (2) yttrium-90 in various preparations, including the ionic chloride, colloidal phosphate, fluoride, hydroxide, and now the silicate ("Y.(SiO)3). Chromic phosphate has been tried (Root et al, 1954), but does not seem to have established itself, possibly owing to the relative difficulty of preparing it.…”

mentioning

confidence: 99%

Malignant Effusions Treated by Colloidal Radioactive Yttrium Silicate

Walter¹

1960

BMJ

View full text Add to dashboard Cite

Distribution of Colloidal Radioactive Chromic Phosphate after Intracavitary Administration

Cited by 35 publications

References 0 publications

Pediatric dosimetry for intrapleural lung injections of³²P chromic phosphate

Pediatric dosimetry for intrapleural lung injections of³²P chromic phosphate

Colloidal Chromic Phosphate: its Biological Behaviour

Malignant Effusions Treated by Colloidal Radioactive Yttrium Silicate

Contact Info

Product

Resources

About

Distribution of Colloidal Radioactive Chromic Phosphate after Intracavitary Administration

Cited by 35 publications

References 0 publications

Pediatric dosimetry for intrapleural lung injections of32P chromic phosphate

Pediatric dosimetry for intrapleural lung injections of32P chromic phosphate

Colloidal Chromic Phosphate: its Biological Behaviour

Malignant Effusions Treated by Colloidal Radioactive Yttrium Silicate

Contact Info

Product

Resources

About

Pediatric dosimetry for intrapleural lung injections of³²P chromic phosphate

Pediatric dosimetry for intrapleural lung injections of³²P chromic phosphate